spacer
home > ict > summer 2021 > how contingency plans became the new normal
PUBLICATIONS
International Clinical Trials

How Contingency Plans Became the New Normal


Over the last decade, there has been increasing interest in mobile health (mHealth) and wearables. The general population has been tracking their steps, checking their heart rates, and monitoring their sleep patterns. Meanwhile, the clinical trial industry has been exploring decentralised trials and remote monitoring options as a way of alleviating the travel burden that patients and CRAs often endure in the course of a trial, especially in rare disease studies where hard-tofind patient populations, as well as the diseases themselves, make trials especially complex. Then the pandemic arrived, and with both patients and clinical trial personnel needing to stay away from sites, the tools and techniques that had been a ‘nice-to-have’ option became a necessity. A year later, the industry has proof that mHealth and remote monitoring deliver clean, concise data far more conveniently than the traditional methods. Now, these new strategies are no longer contingency plans; bringing the clinical trial to the patient is the new normal.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
About the Author

Anthony Poynton, Senior Director, Program Delivery, Rare Disease and Pediatrics, is Premier Research's senior liaison for clinical research in rare diseases and paediatrics, serving as sponsors’ primary point of contact for these clinical programmes and leading teams assigned to these studies. He oversees project scope, schedule, costs, and quality performance to ensure timely project execution and customer satisfaction. Anthony has 17 years of experience in the contract research, pharma, and biotech fields. He joined Premier Research in 2016 as Director of Project Management, overseeing efforts to improve customer satisfaction and drive best practices in innovation and continuous improvement. Prior to joining the company, he held similar positions in the areas of rare and orphan diseases, paediatrics, oncology, gastroenterology, nephrology, and dermatology.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Exogene Raises $2 million for its AI platform to Discover Cell Therapies for Cancer

Oxford, UK, 25th April 2022 / Sciad Newswire / Exogene, a biotech company discovering novel T-cell receptor-based cell therapies, today announces that it has raised US$2 million in funding to develop its artificial intelligence (AI) platform for T-cell receptor discovery.
More info >>

White Papers

Systems Engineering for Complex Portable Medical Device Development

Phillips-Medisize

As the demand for complex, portable medical devices continues to grow, reducing risk and increasing efficiency during the development of these products should be paramount. Taking a systems-engineering (SE) approach to development provides a holistic, organized, and deliberate method for identifying as well as reducing both patient and business risks early in the process. Furthermore, it facilitates efficient progression throughout the entire product development life cycle.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement